Ralf Herold

Head of Regulatory science and Academia workstream (ad interim)

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ralf Herold is the Head of Regulatory Science and Academia Workstream (ad interim) at the European Medicines Agency in the Netherlands. His research areas focus on regulatory perspectives in areas such as brain metastases, Alzheimer's disease, and systemic treatments for ultra-rare cancers. Additionally, he is involved in advancing regulatory science research and fostering innovation in medicine within Europe.

Articles (13)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Collaborators (3)

Anna Maria Gerdina Pasmooij

Utrecht University

NETHERLANDS

View details

Madeline Pe

Head

BELGIUM

View details

Tomas Boran

National Institute on Drug Abuse

CZECH REPUBLIC

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ralf Herold

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

A new European platform for advancing regulatory science research

Novel PET RANO BM 1.0 criteria: Regulatory perspectives on new endpoint definitions in brain metastases

EU regulatory horizons for Alzheimer's disease

How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma.

The European Innovation Network as a hub for medicines innovation in Europe

Report of the European Medicines Agency Conference on RNA-Based Medicines

Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group.

The opportunity for greater patient and public involvement and engagement in drug development and regulation.

Health horizons: Future trends and technologies from the European Medicines Agency’s horizon scanning collaborations

Artificial intelligence in European medicines regulation

The Impact of COVID‐19 on the Initiation of Clinical Trials in Europe and the United States

Therapeutic genome editing: regulatory horizons

Can a Multistakeholder Prioritization Structure Support Regulatory Decision Making? A Review of Pediatric Oncology Strategy Forums Reflecting on Challenges and Opportunities of this Concept

Collaborators (3)

Anna Maria Gerdina Pasmooij

Madeline Pe

Tomas Boran

Make your next move.